By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Resverlogix Corporation 

4820 Richard Road SW
Suite 300
Calgary  Alberta  T3E 6L1  Canada
Phone: 403-254-9252 Fax: 403-256-8495


Company News
Resverlogix (RVX.TO) Release: Recent Publication And Patent Application Referencing Apabetalone Support Its Continued Development And Success 5/23/2017 7:34:58 AM
Resverlogix (RVX.TO) Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial 5/15/2017 9:34:02 AM
Resverlogix (RVX.TO) Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase III Study Of Apabetalone And Provides An Update On Corporate Activities 3/17/2017 7:17:55 AM
Resverlogix (RVX.TO) Announces Receipt Of Notice Of Allowance From The United States Patent And Trademark Office 3/15/2017 8:50:29 AM
Resverlogix (RVX.TO) Reports Positive FDA Type B Meeting On Design Issues Relating To A Proposed Phase IIa Kidney Dialysis Trial 2/23/2017 7:32:35 AM
Resverlogix (RVX.TO) Highlights Unique Properties Of Apabetalone In Both A Rare Muscular Dystrophy (FSHD) And Neurodegenerative Eye Disease 2/13/2017 6:51:13 AM
Resverlogix (RVX.TO) Release: Company Provides Groundbreaking Results In Patients With Severe Kidney Impairments 1/23/2017 10:05:43 AM
Resverlogix (RVX.TO) Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders 12/16/2016 9:50:54 AM
Resverlogix (RVX.TO) Announces Filing Of Quarterly Financial Statements And Management's Discussion & Analysis 12/14/2016 9:45:15 AM
Resverlogix (RVX.TO) Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208) 12/6/2016 6:45:00 AM